ELVN FY 2020 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$9M

Net Income

-$19M

EPS (Diluted)

$-4.31

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$130,000

Balance Sheet

Total Assets

$91M

Total Liabilities

$6M

Stockholders' Equity

$84M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$33,000	+100.0%
Operating Income	-$9M	-$24M	+61.4%
Net Income	-$19M	-$23M	+19.2%